Monday August 3, 2020 0 comments
BOULDER and LONDON -- ArcherDX, Inc., UCL and the Francis Crick Institute today announced an extension to utilize personalized, liquid biopsy-based research assays for the duration of the TRACERx program, a major lung cancer research initiative funded by Cancer Research UK.
Previously reported findings from the TRACERx cohort have transformed understanding non-small cell lung cancer (NSCLC) evolution, and the research team is taking practical steps to make precision medicine for lung cancer patients a reality.
Under the collaboration, ArcherDX and UCL will continue to measure circulating tumor DNA (ctDNA) taken from non-invasive peripheral blood draws at specified intervals.
"We are pleased to continue the collaboration with ArcherDX to examine how minimal residual disease detection relates to cancer relapse, and immune cell responses to immunotherapies," said Professor Charles Swanton, Cancer Research UK's chief clinician and lead researcher of the TRACERx project.
"With more sensitive detection of ctDNA, we gain a longitudinal view of cancer evolution leading to a greater understanding of the complex tumor ecosystem.
“These insights will help us design novel clinical trials that are personalized to more effectively bring new cancer treatments to patients."
"The TRACERx program is a pioneering effort by Professor Swanton and his team at UCL and the Francis Crick Institute,” said Jason Myers, ArcherDX CEO and co-founder.
“We are incredibly proud to continue this collaboration with Professor Swanton and advance the understanding of cancer biology. With our combined expertise and ArcherDX's proprietary Anchored Multiplex PCR (AMP™) chemistry at the core, we will continue to develop better liquid biopsy-based, personalized clinical research assays that have higher specificity and sensitivity with the goal of achieving better outcomes for patients.”
The collaborative group plans to publish peer-reviewed results from the collaboration.